

# PDA Virus Safety & Control of Cell Therapy Products Workshop 2026

## Agenda

**Wednesday, 24 June**

CEST Daylight Time (UTC +2:00)

### Welcome and Overview of the Workshop Scope

09:00 – 09:15 **Moderator: Friedrich von Wintzingerode PhD**, Director, Microbiology and QC Individualized and Cell Therapy, *Genentech, a Member of the Roche Group*

### European Regulations on Viral Safety of Cell Therapeutic Medicinal Products

09:10 – 09:30 **Regulatory Presenter: Johannes Bluemel PhD**, Head of Virus Safety Section, *Paul-Ehrlich-Institut*

### Case Study Procine Virus Contamination Xenotransplantation

09:30 – 09:40 **Academic Presenter: Joachim Denner PhD**, Head of laboratory, *Institute of Virology, Freie Universität Berlin*

### Title to be announced

09:40 – 09:55 **Regulatory Presenter: Ilona Reischl PhD**, *Austrian Agency for Health and Food Safety (AGES)*

09:55 – 10:25 **Coffee Break**

### Case Study on Cell Therapy Contamination

10:25 – 10:35 **Presenter: Cheryl E. Essex MSc**, Head of Contamination Control, R&D Global Quality, *Sanofi*

### Control of HHV6/7 Risk for Allogeneic CAR-T Manufacturing

10:35 – 12:05 **Moderator: Houman Dehghani PhD**, Vice President, *Cabaletta Bio*

12:05 – 13:05 **Lunch Break**

13:05 – 13:15 **Ensuring Viral Safety via Next Generation Sequencing**

### Round Table Discussion

13:15 – 14:45 **Moderator: Friedrich von Wintzingerode PhD**, Director, Microbiology and QC Individualized and Cell Therapy, *Genentech, a Member of the Roche Group*

14:45 – 15:15 **Coffee Break**

### Real Clinical Case Report and Summary of Virus Reactivation in Cell Therapy

15:15 – 04:30 **Moderator: Dayue Chen PhD**, Distinguished Scientist, *Genentech, Inc.*

### Summary of the Workshop and Take-Home Messages

16:30 – 17:00 **Moderator: Friedrich von Wintzingerode PhD**, Director, Microbiology and QC Individualized and Cell Therapy, *Genentech, a Member of the Roche Group*

